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Abstract
CDK 4/6 inhibitors, in combination with endocrine therapy, are the standard of care for patients with endocrinesensitive advanced breast cancer. This class of drug, however, is associated with QT prolongation, which serves as a
surrogate marker for Torsades de Pointes (TdP), a cause of life-threatening ventricular arrhythmias and sudden cardiac
death. The ICH E14 guidance document uses the Bazett formula for reporting of cardio-dynamic and safety ECG data in
clinical trials. While there is substantial familiarity with the Bazett (QTcB) formula (QT/(RR) 1/2), the Fridericia (QTcF)
formula (QT/(RR) 1/3 ) is preferred in the cancer population as it is often more accurate at heart rate extreme. Accordingly, the Fridericia formula is currently the standard adopted by the FDA when submitting QT data for review. At the
King Faisal Specialist Hospital and Research Center, a total of 82 patients with advanced breast cancer, had a baseline
ECG on day 1 before the initiation of ribociclib based therapy. Of the enrolled 82 patients, 19 (23%) were initially
excluded from receiving ribociclib based due to a prolonged QTc >450ms, however, when the QTc-interval was
manually measured and recalculated using Fridericia and Framingham formulae using MDCalC (https//
:www.mdcalc.com),17 of 19 patients successfully received their treatment without any arrhythmogenic effects. Repeat
ECG on day14, and day 1 of cycle 2 demonstrated that none of these patients had QTc exceeding 480 ms. Our data
highlights the complexities of evaluating the QT interval in oncology patients and the utility of the Fridericia/Framingham formulae in this population. Given these ﬁndings, we recommend the adoption of the Fridericia or Framingham formulae for measurement of QTc in all cancer patients exposed to potentially QT-prolonging cancer therapy.
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O

ne of the principle tasks of an oncologist is to
decide whether to proceed or withhold
potentially life-saving cancer treatment, when the
treatment may result in signiﬁcant morbidity. What
would the recommendation be when facing a patient presenting with a prolonged QT interval on the
assumption that the beneﬁts of the proposed cancer
therapy outweigh the risks? QT prolongation has
long served as a surrogate marker for drugs which
prolong ventricular repolarization, and predispose

to recurrent polymorphic ventricular tachycardia,
Torsades de Pointes (TdP), which can cause lifethreatening ventricular arrhythmias that can lead to
sudden cardiac death [1].
The main goal of screening for QT prolongation is
to identify those who are at increased risk for TdP,
so aggressive measures may be implemented to
reduce this risk. In general, cardiovascular adverse
effects are important considerations in all phases of
drug development. It is well known that QT interval
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recorded by electrocardiogram (ECG) reﬂects the
overall duration of ventricular activation and recovery. The electrophysiological measurement of
QT has long served as a surrogate indicator for
predicting increased risk of drug-induced Tdp;
however, the relationship between QT prolongation
and risk of Tdp is imperfect and complex [2].
Great controversy exists over normal values of QT
or the corrected QT (QTc) duration; in the absence
of broad QRS complex, the 99th percentile of QTc is
470 ms for men and 480 ms for women. It is
generally accepted that a QTc above 500 ms is a high
risk factor for Tdp [3]. In this regard, a value of >450
ms irrespective of sex, as suggested by the Food and
Drug Administration (FDA) in their ICH E14 guidance document, is most often utilized in human
clinical trial protocols [4].
The current recommendations for the assessment
of QTc prolongation and arrhythmia potential were
developed in 2005; a dedicated Thorough QT study
was required for all medications to conform to the
ICH E14 guidelines [4]. The ICH E14 guidance
document relied upon the Bazett formula for
reporting of cardiodynamic and safety ECG data in
clinical trials. Subsequently, data has shown the
Bazett corrected formula to be inferior to the Fridericia correction method and is no longer routinely
warranted for reporting by the FDA. While there is
substantial familiarity with the Bazett (QTcB) formula (QT/ (RR) 1/2), the Fridericia (QTcF) formula
(QT/ (RR)1/3) is preferred in the cancer population as
it is often more accurate at heart rate extremes [5].
Accordingly, the Fridericia formula is currently the
standard adopted by the FDA when submitting QT
data for review [6].
Various correction formulas have been developed
to improve QT measurement accuracy. One of the
earliest efforts to acquire a standardized heart rate
correction formula was made by Bazett in 1920
(QTcB ¼ QT/RR1/2). This exponential method
enabled the comparison of QT intervals at different
heart rates. In fact, in case of altered cardiac frequencies, heart rates >100 beats/minute or <60
beats/minute, the correction according to Bazett is
not ideal because the value is overestimated or
underestimated, respectively [7]. Since then,
numerous correction formula have been generated.
The Fridericia exponential correction (QTcFri ¼ QT/
RR1/3) has the same limitations at slow heart rates,
but is considered to be more accurate than Bazett’s
correction at faster heart rates [8]. The Framingham
linear method (QTcFra ¼ QT þ 0.154(1-RR) results
in more uniform rate correction over a wider range
of heart rates [9]. Among these, the most widely
used in clinical practice is the Bazzet formula which

becomes integrated into computerized ECG acquisition carts and is still utilized today by many clinicians worldwide. Interestingly, different studies
suggested different formulae to be superior, but all
had one thing in commondthe inferiority of QTcB
[10].
How do these mechanisms translate into clinical
practice? In line with the inferiority of the Bazett
formula, Patel et al. [11] evaluated four methods of
QT correction in more than 6,500 patients with sinus
tachycardia >100 beats/minute for development of
coronary artery disease, heart failure, and mortality.
At a median follow-up of 4.5 years, annualized
cardiovascular events rate were 2.3% and mortality
rate was 2.2%. QT prolongation was 39% by Bazett,
6.2% by Fridericia, 8.7% by Framingham, and 8.7%
by Hodges. It was evident that Bazett correction
formula overestimated the number of the patients
with a prolonged QT and was not associated with
morality. Furthermore, a comparative analysis of
QTc assessment using ﬁve different correction
formulae performed in >6,500 patients concluded
that Fridericia and Framingham correction formulae
showed the best rate correction and signiﬁcantly
improved prediction of 30-day and 1-year mortality;
Bazett performed worst. The authors suggest that
the use of QTc Bazett correction formula could
overestimate the number of patients with potential
dangerous QTc prolongation, leading to unnecessary withholding of cancer therapy. Therefore, the
questions arise whether QTc Fridericia should
become the next clinical standard replacing QTc
Bazett for hospital-based QT monitoring [12]. In a
retrospective analysis of 130 patients in a Phase I
oncology clinical trial, Borad et al. [13] assessed the
effect of QTc formula selection on patient eligibility
by comparing QTc interval values using seven
formulae (Bazett, Fridericia, Framingham, Hodges,
Mayeda, Van de Water, and Wohlfart). QTc values
cutoff used to deﬁne prolongation were >470 ms
and >450 ms for females and males, respectively.
Ineligibility rates ranged from 3.1% to 17.7% (Framingham: 3.1%, Van de Water: 3.1%, Hodges: 3.1%,
Wohlfart: 3.1%, Fridericia: 3.9%, Bazett: 10.8%, and
Mayeda: 17.7%). They clearly demonstrated the
profound effect of these formulae to impact patient
selection patient to receive chemotherapy [13].
In the battle against breast cancer, CDK 4/6 inhibitors (palbociclib, ribociclib, and abemaciclib)
have emerged as new potential therapeutic options
for treatment of advanced-stage hormone
receptorepositive, HER2enegative breast cancer.
One of the safety considerations for ribociclib is its
potential for QTc prolongation; the product monograph for ribocliclib recommends three ECGs, at
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baseline, Day 15, and Cycle 2 Day 1, to ensure that
the corrected QT (QTc) interval is within the normal
range. Ribociclib has been proven to improve progression-free and overall survival, resulting in FDA
approval in combination with endocrine therapies
[14]. As per FDA approval, treatment with ribociclib
should be initiated only in patients with a QTc value
of 450 ms.
At King Faisal Specialist Hospital and Research
Center, a total of 82 patients with advanced breast
cancer had a baseline ECG performed on Day1
before the initiation of ribociclib therapy. A
computerized ECG was analyzed primarily using
MAC 5500 HD system (GE Healthcare, USA), which
performs measurement on global waveforms utilizing the Bazett formula (Table 1). Of the enrolled
82 patients, 19 (23%) were initially excluded to
receive ribociclib due to a prolonged QTc > 450 ms.
However, when the QTc interval was manually
measured and recalculated using MDCalC (https//
:www.mdcalc.com) which is based on Fridericia and
Framingham formulae, 17 of 19 initially excluded
patients were allowed to receive their treatment.
ECG was repeated on Day 14 of Cycle 1, and Day 1
of Cycle 2 demonstrated that none of these patients
had QTc exceeding 480 ms. Patients were followedup for an additional 12 weeks, and no cardiac issues
were reported. When QTc values obtained by the
four formulas were compared, one-way analysis of
variance revealed a signiﬁcant difference between
the means of the three formulae ( p < .001). Post hoc
analysis indicated that the mean score for Bazett

(471 ± 12 ms) was signiﬁcantly different from Fridericia (439 ± 12 ms) and Framingham (434 ± 13 ms)
( p < .001). However, the mean scores of Fridericia
and Framingham showed no signiﬁcant difference
( p ¼ .75). Appropriate ethical review boards
approved the data collection (RAC# 2052e029); patients provided written informed consent as per
hospital policies.
Our data highlights the complexities of evaluating
the QT interval in oncology patients and the utility
of the Fridericia/Framingham formulae in this
population. The Bazett formula was associated with
longer QTc intervals which could lead to prevention
or abandonment of effective cancer therapy.
Consequently, these data should incite prompt
modiﬁcation of the QTc calculation formula provided by computed ECG machines. Furthermore,
uniform criteria and guidelines for selection of QTc
formula need to be developed. Formula-speciﬁc
QTc thresholds also need to be speciﬁed.
Given that the Bazett’s formula is widely adopted
in everyday clinic practice, one cannot escape the
conclusion that the arrhythmogenic potential of QT
prolongation is exposed to clinical biases that
extend beyond the pharmacologic characteristics of
targeted molecules. Indeed, not all clinicians are
aware that Bazett formula may not be optimal to use
or that their computerized ECG machines are using
Bazett formula as a default. Given these ﬁndings, we
recommend the adoption of Fridericia or Framingham formula for measurement of QTc in all cancer
patients exposed to potentially QT prolonging

Table 1. Comparison of QTca Using Different Formulae.
Computerized ECG (MAC 5500 HD system)

MDCalC.com

Pt #

Heart rateb

QT, ms

QTc, ms

Bazett

Fridericia

Framingham

Hodges

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

82
93
103
71
99
93
94
75
115
112
91
81
87
103
87
85
89
79
111

398
370
372
442
376
366
382
424
350
360
368
406
394
352
400
386
372
406
350

465
460
487
480
482
455
477
473
484
491
452
471
474
461
481
459
452
465
476

465
460
487
481
483
456
478
474
485
492
453
472
474
461
481
459
452
466
476

442
428
445
468
444
424
444
457
435
443
423
449
446
421
449
434
424
445
430

439
425
436
466
437
421
438
455
424
432
420
446
442
416
448
431
422
443
421

437
428
447
461
444
424
442
450
446
451
422
443
441
427
400
430
423
406
439

a

Measured in milliseconds. bMeasured in beats per minute.
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cancer therapy which is more aligned with a true
corrected QT interval. In clinical practice, the
adoption of Fridericia or Framingham formula for
QTc could result in more cancer patients receiving
life-sustaining therapy.
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